Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atypical B cells in glioblastoma patients with and without dexamethasone
NL-OMON49155Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of dexamethasone in glioblastoma (GBM) (2 arms), sponsored by Vrije University Medical Center. Primary endpoints: Frequency and phenotypic characterization of atypical B cells in blood and Functional characterization of atypical B cells including IL-10 expression. Started Mar 2020; status: active, not recruiting.
02
Drugs
dexamethasone
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON49155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49155.